Merus N.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Merus N.V. - overview
Established
2003
Location
Utrecht, -, Netherlands
Primary Industry
Biotechnology
About
Founded in 2003 and based in the Netherlands, Merus N. V. operates as a biotechnology company that develops the Multiclonics platform used to screen and generate molecular and cell-based bispecific antibody therapeutics. The company has raised venture funding rounds from private equity investors, including Pfizer Venture Investments, Life Sciences Partners, and BVF Partners.
In May 2016, the company was listed on the Nasdaq for an IPO (Initial Public Offering) under the ticker symbol MRUS. In August 2023, Merus N. V. raised USD 150 million in a Private Placement, selling 6.
82 million shares at USD 22 on the Nasdaq Global Market. The firm as of January 2024, is led by its President and CEO, Bill Lundberg. The company's R&D team offers IgG antibody therapeutics through the Multiclonics platform that discovers and screens bi-specific and tri-specific antibodies capable of binding two or more targets for the treatment of patients with cancer, as well as infectious and inflammatory diseases. Merus is also working on clinical trials for drug candidates, namely MCLA-128, MCLA-129, MCLA-158, MCLA-145, and ONO-4685.
Merus N. V. generates revenue by collaborating with pharmaceutical and biotechnology companies and academic institutions to extend its platform and product candidates' reach and capabilities.
Current Investors
Novartis Venture Fund, EuroTransBio, Agentschap NL
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.merus.nl
Company Stage
Mature
Total Amount Raised
Subscriber access only
Merus N.V. - timeline of key events
Merus N.V. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 741,232.244 | 1,730,965.095 | 2,194,470.076 | 3,009,551.85 | 15,372,485.28 | 37,143,631.285 | 31,896,937.888 | 29,608,820.66 | - | - | - |
| % Revenue Growth (YoY) | - | 133.5% | 26.8% | 37.1% | 410.8% | 141.6% | (14.1%) | (7.2%) | - | - | - |
| EBITDA (USD) | (12,808,174.368) | (22,805,431.918) | (25,359,060.876) | (30,370,019.732) | (48,942,150.01) | (45,129,134.055) | (58,181,143.526) | (72,021,826.041) | - | - | - |
| Operating Income (USD) | (13,158,864.892) | (23,141,528.747) | (25,573,290.884) | (30,629,024.93) | (49,301,594.887) | (45,882,683.939) | (59,873,250.156) | (75,198,890.07) | - | - | - |
| Operating Margin | (1775.3%) | (1336.9%) | (1165.4%) | (1017.7%) | (320.7%) | (123.5%) | (187.7%) | (254.0%) | - | - | - |
| % EBITDA Margin | (1728.0%) | (1317.5%) | (1155.6%) | (1009.1%) | (318.4%) | (121.5%) | (182.4%) | (243.2%) | - | - | - |
| NET Income (USD) | (13,161,521.638) | (23,126,915.842) | (25,734,240.889) | (52,274,775.563) | (82,614,674.752) | (28,664,423.418) | (56,433,043.956) | (84,814,590.689) | - | - | - |
| % Net Margin | (1775.6%) | (1336.1%) | (1172.7%) | (1737.0%) | (537.4%) | (77.2%) | (176.9%) | (286.5%) | - | - | - |
Merus N.V. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Merus N.V. | - |
Displaying 1 - 1 of 1
Merus N.V. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.